Instil Bio Elects Director and Ratifies Auditor

Instil Bio ( (TIL) ) just unveiled an update.

On May 28, 2025, Instil Bio, Inc. held its Annual Meeting of Stockholders where two key proposals were voted on. Stockholders elected Bronson Crouch as a Class I director and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, indicating strong shareholder support and continuity in the company’s governance and financial oversight.

The most recent analyst rating on (TIL) stock is a Buy with a $52.00 price target. To see the full list of analyst forecasts on Instil Bio stock, see the TIL Stock Forecast page.

Spark’s Take on TIL Stock

According to Spark, TipRanks’ AI Analyst, TIL is a Underperform.

Instil Bio’s stock faces considerable challenges primarily due to severe financial instability, as evidenced by the absence of revenue and ongoing losses. The technical analysis indicates a bearish trend, with the stock significantly underperforming compared to its moving averages. Additionally, the company’s valuation metrics, including a negative P/E ratio and no dividend yield, further underscore the high risk associated with this investment. These factors combine to give Instil Bio a low overall stock score.

To see Spark’s full report on TIL stock, click here.

More about Instil Bio

Instil Bio, Inc. operates in the biotechnology industry, focusing on the development of innovative cell therapies for cancer treatment.

Average Trading Volume: 160,663

Technical Sentiment Signal: Buy

Current Market Cap: $158.8M

See more insights into TIL stock on TipRanks’ Stock Analysis page.